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Abstract
With the advent of Next Generation Sequencing the identification of mutations in the genomes of healthy and diseased
tissues has become commonplace. While much progress has been made to elucidate the aetiology of disease processes in
cancer, the contributions to disease that many individual mutations make remain to be characterised and their downstream
consequences on cancer phenotypes remain to be understood. Missense mutations commonly occur in cancers and their
consequences remain challenging to predict. However, this knowledge is becoming more vital, for both assessing disease
progression and for stratifying drug treatment regimes. Coupled with structural data, comprehensive genomic databases of
mutations such as the 1000 Genomes project and COSMIC give an opportunity to investigate general principles of how
cancer mutations disrupt proteins and their interactions at the molecular and network level. We describe a comprehensive
comparison of cancer and neutral missense mutations; by combining features derived from structural and interface
properties we have developed a carcinogenicity predictor, InCa (Index of Carcinogenicity). Upon comparison with other
methods, we observe that InCa can predict mutations that might not be detected by other methods. We also discuss
general limitations shared by all predictors that attempt to predict driver mutations and discuss how this could impact high-
throughput predictions. A web interface to a server implementation is publicly available at http://inca.icr.ac.uk/.
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Introduction
Many cancers arise as a result of the acquisition of a series of
fixed DNA sequence abnormalities, termed mutations, which
ultimately confer a growth advantage upon the cells in which they
have occurred [1,2,3,4]. These mutations can have several impacts
on the gene in or near which they reside. Mutations that
contribute to disease initiation or progression, often by altering the
protein product directly, are termed ‘‘driver’’ mutations, whereas
those mutations that are a result of the inherent genetic instability
of the cancer, confer no selective advantage to the cell and do not
contribute to disease progression are termed ‘‘passenger’’ muta-
tions.
With the advent of Next Generation Sequencing (NGS) the
identification of mutations in the genomes of healthy and diseased
tissues has become commonplace providing a new avenue to
discover potential genotypes underlying the molecular causes of
cancers [5]. Key to this endeavor is the ability to determine which
mutations are contributing to the disease process. The most
common mutational event in cancer that changes the protein
product is a missense substitution, where usually a single base
substitution changes the protein product by a single amino acid.
However the consequence of these mutations still remains
challenging to predict.
There is a large body of work documenting the consequences of
inherited missense mutations, as they comprise a large part of the
repertoire of human disease variants as evidenced in the OMIM
[6] and HGMD databases [7]. Studies show that disease-
associated mutations commonly impact protein folding, protein
stability, and protein-protein interactions (PPIs) [8] thus altering
protein function. What is key to determining the molecular and
hence biological impact of a mutation, is its location within the
protein structure and the molecular function of residues affected
[9]. Many studies have shown that both the evolutionary
conservation of the mutated residue, the severity of difference in
physiochemical properties of the substitution and the structural
attributes of the residues involved, are all indicative of the
disruption of the protein, with more ‘‘diverse’’ substitutions
resulting in disease [10]. This also includes inherited missense
mutations within cancer predisposition genes such as those in
BRCA1 [11,12].
More recently, studies have compared the conservation of
somatically acquired cancer mutations with neutral missense
mutations suggesting [13] [14] that both the evolutionary
structural and functional conservation of the mutated residue
and its local environment, combined with the severity of the
substitution discriminate between cancer associated and neutral
mutations.
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Sequence and protein structure have often been used to predict
whether non-synonymous single nucleotide polymorphisms
(nsSNPs) could be disease causing, as well as assisting in ranking
or prioritising candidates for experimental validation. Sequence
conservation has been used to predict which mutations would not
be tolerated within a protein, and are often used as a proxy to
identify disease-causing mutations [15,16,17,18,19,20,21,22]. Sim-
ilarly, protein structure has been used for estimating how
disruptive a missense mutation maybe [18,19,23,24,25,26,27,28].
Recently Reva et al. [29] successfully used comprehensive multiple
sequence alignment of proteins to create a functional impact (FI)
metric to score amino acid substitutions. Other methods include
filter-based algorithms to prioritize pathogenic mutations [30].
While several structure-based predictors exist for estimating
general pathogenic effects of missense mutations these are not
specifically oriented towards cancer mutations and do not benefit
from the comprehensive structural detail of protein interfaces.
From a structural perspective the structural impact of a driver
mutation is dependent on whether the protein is an oncogene or
tumour suppressor. The structural consequences of mutations
within tumour suppressors, where protein function is ablated, are
often similar to those in inherited diseases, in that they impact on
protein stability and folding. Mutations can also disrupt active sites
or ligand binding sites, whether directly by occurring in or near
the site or indirectly by destabilising the site’s structure, will also be
severely detrimental to the protein’s function. In contrast
mutations in oncogenes, where the protein is activated, are found
in loops and unstructured regions of proteins and not in the
protein core [31,32].
When considering the impact of a mutation, protein-protein
interfaces are also important regions of the protein to consider
since they are responsible for mediating protein interactions within
the cell. Protein interfaces have discernible characteristics such as
complementarity in shape and electrostatic charge and the
presence of hydrophobic patches [33,34]. Hydrophilic residues
are more frequent in interfaces facilitating transient interactions,
whereas interfaces in more permanent subunit associations in
complexes often have hydrophobic patches.
Recent analyses on protein structures in the Protein Data Bank
Europe (PDBe) [35,36] have revealed a comprehensive set of
protein interfaces which were deposited in the Protein Interfaces,
Surfaces and Assemblies (PISA) database [37]. Coupled with
genome-wide NGS mutation data, this gives the opportunity of
exploring how mutations manifest structural defects in proteins
and therefore provide useful insights into how they may cause
cancer genome phenotypes. Examples of interface mutations that
disrupt protein-protein interactions have been previously docu-
mented [38] and the value of molecular-level annotation of
proteins with respect to interfaces has recently been demonstrated
[39] by predicting the effect of mutations using interface proximity
and offering explanations for pleiotropy and locus heterogeneity in
terms of mutation location with respect to interfaces.
With the increasing amounts of sequence and mutation data
from NGS experiments, there is an accompanying need to develop
better ranking and prediction tools to assess and characterize
cancer mutations computationally. Here, we describe a new
predictor, InCa (Index of Carcinogenicity), based on criteria
derived from a large scale analysis of cancer driver mutations from
the COSMIC database and the HapMap mutations in the 1000
Genomes (1k) project. We show that by focusing on structure and
interface information, our parameters can be used to obtain
similar or better prediction than previous methods that predict
severity of mutations in cancer data sets based on structure and
sequence conservation, such as those described in [40] and [22]
and detect mutations that are not detected by some of these
methods. When we compare predictions of InCa and CHASM
[22], another cancer-specific missense driver mutation predictor,
we also find that relevant mutations are detected by both methods
that are not detected by the other. We discuss general caveats
affected by all current prediction methods and how they affect
predictions of driver mutations in the context of cancer biology.
Methods
Protein structure data and protein interface data
Protein interfaces were obtained from PISA and assembled into
an in-house database which was further expanded with data from
the Structure Integration with Function, Taxonomy and Sequence
(SIFTS) initiative database [35] allowing translation of PDB to
UniProt coordinates. PISA interfaces with complexation signifi-
cance scores (CSSs) of zero and an interface area of ,400 A˚ were
considered as ambiguous and excluded from our analysis. Using
the PISA quaternary structure definitions we computed intra- and
inter-molecular minimum atomic contacts for residues, as well as
the centre of gravity for each interface. Relative accessible and
buried surface areas (ASA and BSA) were calculated from the
PISA absolute ASA and BSA values as the fraction of the
accessible area of the respective amino acid in the tripeptide Gly-
X-Gly [41]. Secondary structure DSSP [42] assignments were
obtained from SIFTS and simplified to three states: helix, H, beta
sheet/strand, E, and coil, C. Non-human PDB interfaces were
filtered out using PDB chain to taxonomy mappings (ftp://ftp.ebi.
ac.uk/pub/databases/msd/sifts/text/pdb_chain_taxonomy.lst).
To obtain background distributions of amino acid frequencies in
our data set, we used a non-redundant human list of proteins from
NCBI (ftp://ftp.ncbi.nih.gov/mmdb/nrtable/nrpdb.060111) with
p-value for similarity cutoff of 10e-80. The UniProt database [43]
was parsed and the annotations for post-translational modifica-
tions and disulphide bonds were added to the residue data. A
further comprehensive set of post-translational modifications were
obtained from Phosphosite [44]. We included acetylation,
methylation, O-GlcNAc modification, phosphorylation, sumoyla-
tion and ubiquitination. Only the sites obtained via high
throughput mass spectrometry were taken to reduce any
investigation bias.
Neutral mutations, mutations in cancer genomes and
driver mutations
Non-synonymous SNPs from non-diseased individuals were
downloaded from the 1000 Genomes (1k) Project [45]. Those
from somatic cancer genomes were downloaded from COSMIC
version 64 [46]. The mutations in both studies were annotated to
transcripts in the Ensembl database [47,48] by alignment to the
reference human genome. The mutations were sorted with respect
to protein topological area by their interface area and CSS (if the
residue is in an interface), relative accessible surface area (relative
ASA) and buried surface area (relative BSA) (Table S1).
Driver mutations were taken from [22], which is a mutation list
from COSMIC in putative oncogenes and tumour suppressor
genes identified using a variant of the 20/20 rule [49]. We
obtained the most recent list from the author’s url (http://wiki.
chasmsoftware.org/index.php/CHASM_DL) downloaded on
21.12.2012.
Out full data frame of mutations is available in Dataset S1.
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Biases in frequency of mutation classes and
physicochemical dissimilarity of residues
Overrepresentation of mutations classes was calculated by
constructing contingency tables and applying Fisher’s exact tests
correcting for multiple testing using false-discovery rate. Details
are provided in supplementary methods in Text S1. Details of
physicochemical dissimilarity for mutations are given in supple-
mentary methods in Text S1 and Table S2.
Results
1000 Genomes and driver mutation comparison
overview
Our compiled list of neutral and cancer driver mutations
mapping to proteins with structure comprised 2412 unique single
nucleotide polymorphisms from the 1000 Genomes (1k) project
and 3808 unique mutations from cancer drivers. These were
mapped to 1207 and 57 unique proteins (UniProt IDs) respec-
tively. 3 mutations and 23 proteins overlapped in the two data sets
(Figure S1 A–B).
The most frequently mutated proteins with driver mutations
with were p53, PTEN, EGFR, CDKN2A and PIK3CA, all of
which are highly studied oncogenes or tumour suppressors.
Conversely, among the proteins most frequently mutated with
neutral mutations were immune system proteins like HLA class II
histocompatibility antigen, HLA-DPB1 (P04440). The amount of
mutations for the top genes with the most neutral mutations and
most driver mutations are shown in Table S3. The average for
drivers and neutral proteins were 2.0 and 54.2 respectively, and
the mode 1 and 5 respectively. The distribution of mutations per
protein had a longer tail for driver proteins (Figure S2).
Cancer driver mutations are less conservative than
neutral mutations
To compare the neutral and driver mutations, it was necessary
to ensure that there was no underlying bias in the observed amino
acid frequencies in 1k and COSMIC. The normalised frequencies
were very similar in the two datasets and were also highly
correlated with those observed for both UniProt and the PDB as a
whole (Figure S3). There were two exceptions, with both Ser and
Pro residues being slightly under-represented in both the
structurally constrained datasets.
We calculated several measures to compare of the nature and
the conservation of the mutations in driver and neutral datasets.
Cancer driver mutations exhibited significantly higher physico-
chemical differences between the wild-type residue and the
mutant, than neutral mutations, suggesting that in general they
exhibit less conservative substitutions (Figure S4). This observation
was supported by the lower BLOSUM substitution scores, and the
lower Dayhoff substitution scores demonstrated by the driver
mutations, indicating that these mutations were less conservative
than neutral mutations.
Driver mutations also exhibited higher functional impact (FI)
scores [29], supporting the hypothesis that driver mutations are
both less conservative (Figure S4) and occur in both functionally
and structurally conserved regions of the protein. However, in a
number of cases the FI score could not be calculated because the
mutation fell outside a region of the requisite multiple sequence
alignment. There were also several 1k mutations where the FI
score was significantly high. Further analyses are required to
determine whether these mutations will disrupt the protein
function leading to a pathogenic impact, or whether these are
false positive results. Either way, the development of alternative
methods to predict the carcinogenicty of mutations is important.
To ensure these distribution differences were not due to a biased
artefact in the data for driver mutations having more extensive
interface or interaction partner annotation, we obtained the
corresponding distributions for the reduced set of 23 proteins in
the intersection of proteins with driver mutations and proteins with
neutral mutations. Using this set reduced the number of mutations
from 5500 to 1677, a 30% reduction. We observed the same
differences in distribution, with only two cases being below
statistical significance at the 0.05 level, namely FI scores for
mutations in buried residues and mean distance to interface for
mutations in interface areas (Figure S5). However, because this
reduced set greatly reduces the number of mutations available for
analysis, we suspect this loss of significance is likely due to
insufficient data.
Driver biases in topology, secondary structure and amino
acid composition
As we wanted to incorporate structural features in our
prediction algorithm we first investigated which structural
parameters to include. Several studies have suggested that
cancer-causing mutations preferentially occur in particular loca-
tions within a protein structure, for instance temperature-sensitive
Table 1. Summary of top mutation types in each category enriched in drivers.
secondary structure buried interface surface
coil TRI
sheet CRR,LRR
helix LRR
any C,H,L,W,Y,LRP,LRR,VRD G,L,GRE,LRP,LRR,GRV,RRP Y,LRR,GRV
doi:10.1371/journal.pone.0084598.t001
Table 2. Contingency tables for post-translational
modifications, disulphide bonds and electrostatic (h-bonds
and salt bridges) interface bonds in mutated residues.
NO PTM PTM NO SS SS
NO interface
bond
interface
bond
neutral 2387 25 2409 3 1987 425
driver 3019 69 3082 6 2077 1011
p 0.0007117 0.7398 ,2.2e-16
P-values are calculated with a Fisher’s test with a two-sided alternative
hypothesis.
doi:10.1371/journal.pone.0084598.t002
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(TS) mutations often occur in buried regions of the protein. We
investigated these biases in topology of mutations as a whole and
investigated whether they occurred at an interface, on the protein
surface or were buried and we also recorded their secondary
structure (helix (H), sheet (E), or coil (C)).
In general, mutated residues occurred less frequently in buried
positions and more frequently in surface accessible positions
(Figure S6 A,C). This tendency was even greater for the neutral
mutations alone. Driver mutations occurred slightly more
frequently in interfaces. Interestingly, driver mutations occurred
more often in coils and beta sheets whereas neutral mutations
occurred less frequently in a-helices (Figure S6 B,D). In both
datasets arginine was the most frequently mutated residue despite
its highly redundant codon usage. We further calculated the
normalised frequency and observed/expected ratio of the corre-
sponding mutation classes for the reduced set of 23 proteins
containing both neutral and driver mutations. We observed the
same differences, with driver mutations occurring more frequently
in interfaces (Figure S7).
To further investigate the differences in the distribution of
driver and neutral mutations, the data was partitioned by
secondary structure, topology and mutated wild type residue.
Several biases were discernible in the type of amino acid mutated,
particularly when the data was partitioned by secondary structure
type (Figure S8): tryptophan residues were more often mutated in
drivers, as well as buried cysteine residues in beta sheets and coils,
buried hydrophilic residues (aspartate, glutamate, histidine and
phenylalanine) and interface glycine residues.
Several types of amino acid substitutions were enriched in
drivers (Figure S9, S10). Table 1 summarises the top 10
significantly enriched mutation types in each category. Both
glycine to valine and glutamate to glycine substitutions were
enriched in interface areas and leucine to proline mutations in
interface helices. These mutations were all predicted to be
deleterious from their physicochemical parameters. In particular
proline is known to be a ‘‘helix breaker’’ [50,51] and such
mutations to a proline residue within a helix are likely to have a
considerable structural impact. Some amino acid substitutions
were never observed in either data sets (Figure S9). We found that
amino acid substitutions requiring two or more nucleotide
substitutions (using values from the genetic code matrix) were
never observed in neutral mutations, whereas in drivers, several
cases of different amino acid substitutions requiring two or more
nucleotide substitutions were observed. However, in general,
amino acid substitutions requiring only 1 nucleotide substitution
were more prominent and the non-observed amino acid substi-
tutions corresponded mostly to those requiring 2–3 nucleotide
substitutions.
Conversely, alanine isoleucine and valine residues were mutated
more frequently in the neutral dataset, especially on the protein
surface (Figure S8), suggesting that when these residues are located
on the surface of the protein they can tolerate mutations with little
detrimental effects. Buried valine to isoleucine mutations were also
enriched in the neutral dataset probably facilitated by their
similarity in physicochemical properties (Figure S9B).
Driver mutations were significantly enriched in interface
electrostatic bonds and post-translational modifications (Table 2).
The enrichment of cysteine mutations in drivers prompted us to
examine whether they could disrupt disulphide bond formation. In
the majority of cases, mutated cysteines did not participate in
disulphide bond formation and when they did, there was no
statistically significant enrichment in driver, indicating that the
mutation defects cannot be attributed to their loss. Interestingly
the immediate vicinity (5 A˚ radius) of mutated buried cysteine
drivers was highly enriched in cysteine residues (Figure S11),
suggesting that the change in physicochemical properties may itself
contribute to the mutation severity, or that the proteins in our
dataset do not for disulphide bonds. This would be the case if
many proteins in our data set are located to the cytoplasm, as
opposed to localised to organelles and excretion, where disulphide
bond formation occurs following their synthesis in the endoplasmic
reticulum.
Driver mutations are located near protein interfaces
Driver mutations occurred closer to interface binding sites than
neutral mutations (Figure S3) suggesting that mutations that
interface disruption may be a factor in cancer pathogenicity. To
Table 3. Area propensities of mutations by accessibility.
area and accessibility
normalised frequency of
driver/neutral in full set
normalised frequency of driver/neutral in
intersection set
interface, ,10% accesssible 3.63 11.12
interface, 10–30% accesssible 2.52 4.49
interface, .30% accesssible 1.26 1.52
buried, ,10% accesssible 1.79 1.47
surface, 10–30% accesssible 1.55 2.38
surface, .30% accesssible 0.87 0.90
For each area, the percentages denote the relative ASA. Ratios denote the driver/neutral fraction. Values for the set of 23 proteins which contain both neutral and driver
mutations is shown on the right.
doi:10.1371/journal.pone.0084598.t003
Table 4. Ratios of COSMIC/1k of normalised hydrophobicity
propensities by accessibility.
PhiPhi PhiPho PhoPhi PhoPho
interface, ,10% accesssible 5.47 6.48 4.73 3.32
interface, 10–30%
accesssible
3.05 4.23 4.19 2.28
interface, .30% accesssible 1.28 2.13 2.20 1.50
buried 3.13 3.25 3.10 1.44
surface, 10–30% accesssible 1.93 2.34 2.46 1.51
surface, .30% accesssible 0.90 1.39 1.45 1.11
‘‘Phi’’ denotes hydrophilicity and ‘‘Pho’’ denotes hydrophobicity.
doi:10.1371/journal.pone.0084598.t004
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investigate if the position of the mutation within the interface was
important we divided mutated residues into groups depending on
their relative accessible surface area (ASA) both in the monomeric-
unbound state, and their corresponding accessibility when
contributing to a multimer. We analysed these accessibilities and
compared their frequency in drivers and 1k datasets (Table 3).
Mutations occurring in interfaces in multimers that were in
partially accessible residues in the monomer, were enriched in the
driver dataset, suggesting that these were the most deleterious
residue positions when combined in an interface. We calculated
the same ratios for the intersection set of 23 proteins in the
intersection. We observed the same pattern with partially
accessible or buried residues in interfaces being enriched in driver
mutations.
We further analysed the driver and neutral mutations by also
taking into account the residue hydropathy changes between wild
type and mutant (Table 4).Hydropathy transitions (hydrophilic to
hydrophobic and vice versa) were enriched in drivers, with the
enrichment becoming stronger for residues of lower accessibility.
The only notable exception was the hydrophobic to hydrophilic
interface mutations, which showed slight enrichment in neutral
mutations. It is possible that such mutations may be better
tolerated in adjoining exposed hydrophilic interface patches.
Together these data indicate that the disruptions that cause the
cancer phenotype in interface areas are likely to occur from
Figure 1. Hydrogen bond enrichment in interface residues for charged and polar residues in driver mutations. Densities (denoted P(x))
are shown for mutations of each amino acid in both sets with their associated p-values comparing 1k and drivers with a two-sample Wilcoxon test
using a one-sided alternative hypothesis.
doi:10.1371/journal.pone.0084598.g001
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mutations that are buried or partially accessible in the monomeric
unit. This effect is exacerbated when the residue hydropathy is
altered, suggesting that partially exposed interface residue
mutations in drivers may act primarily by distorting the protein
interface shape. This effect may be more deleterious than the loss
of hydrophobic contacts or electrostatic interactions potentially
imposed by mutations found in highly accessible interface residues.
Driver mutations disrupt electrostatic interactions across
interfaces
Formation of hydrogen bonds and salt bridges across the
opposing sites of the interface plays a pivotal role in interface
stabilisation [52]. To investigate whether mutations in drivers
more often occurred in interface residues critical for electrostatic
interactions, we calculated the maximum and mean hydrogen and
salt-bridge bonds for each mutated wild type residue side chain.
Compared to drivers, neutral mutations occurred in interface
residues enriched for non-hydrogen bonded amino acids and in
the majority of cases, the proportion of residues forming one or
more hydrogen bonds, was significantly lower (Figure 1).
Driver mutations often occurred in amino acids that contribute
a higher number of hydrogen bonds across the interface. To a
large extent, these patterns were observed for salt bridges too but
differences were statistically significant for glutamic acid and
histidine only (Figure S12).
Compositional differences between the drivers and
neutral mutational microenvironments
A previous study [9] has shown that structural disruption by a
mutation of the local environment correlates with the pathoge-
nicity of a mutation. These include whether a mutation cause a
steric clash, introduces a cavity in the protein, and estimate the
local change in stability of a protein. Studies have also indicated
that these metrics are dependent on both conformation and
resolution of the protein structure, so we developed a ‘‘fuzzy’’
packing metric to describe the mutated residue’s microenvirion-
ment, which consisted of the normalised frequency of each amino
acid residue in the vicinity of the mutated residue within a 5 A˚
radius. This metric was calculated on both the isolated monomer,
and the PISA derived multimers so that we could capture
information on both inherent and the interfacial microenviron-
ments. Where more than structure was available, data from all the
available structures were combined.
Although overall, neither drivers nor neutral proteins and their
interfaces exhibited global compositional differences, for several of
the 20 amino acids there were statistically significant composi-
tional differences between the driver and the neutral interior and
interfacial microenvironments (Figure S13, as well as Dataset S2
for full listings). We observed instances of polar or charged residues
being in the vicinity of mutated polar or charged residues
significantly more often in drivers, suggesting that disruption of
electrostatic interactions or electrostatic patches of proteins are
important in contributing to the cancer phenotype. We further
fine-tuned the interface compositional analysis by subgrouping
substitutions by wild type and mutant amino acid. While the
differences did not reach significance, we observed several
substitutions that represented a loss of electrostatic interactions
in the context of the neighbouring residues. In several instances,
such as mutations of phenylalanine to serine substitutions (Figure
S14A) it is possible that cation-pi interactions with arginine
residues on the opposite side of the interface may be abolished.
Such interactions have been previously shown to be important
Figure 2. ROC curve for InCa and other mutation predictors.
Shown are the standard metrics averaged using 10% randomly
withheld annotations and 100 repetitions at each point. ‘‘simple
structure’’ denotes a model without using frequency profiles of
neighbouring residues. A model denoted ‘‘InCa FI’’ is a combined
model using FI as a parameter. AUC values are shown next to the
names.
doi:10.1371/journal.pone.0084598.g002
Table 5. ROC curve and prediction parameters for optimal thresholds in all tested methods.
optimal
threshold specificity sensitivity accuracy tn tp fn fp npv ppv
1-
specificity
1-
sensitivity 1-npv AUC
simple structure 0.53 0.77 0.72 0.74 4125 4845 1880 1250 0.69 0.79 0.23 0.28 0.31 0.82
InCa 0.54 0.83 0.77 0.80 4424 5225 1550 901 0.74 0.85 0.17 0.23 0.26 0.88
FI 0.67 0.74 0.54 0.63 3969 3680 3089 1362 0.56 0.73 0.26 0.46 0.44 0.69
InCa FI 0.56 0.85 0.75 0.79 4495 5106 1722 777 0.72 0.87 0.15 0.25 0.28 0.89
Poly-phen2 0.53 0.65 0.80 0.73 3463 4189 1062 1835 0.77 0.70 0.35 0.20 0.23 0.75
SIFT 0.52 0.75 0.70 0.73 3582 3319 1441 1173 0.71 0.74 0.25 0.30 0.29 0.77
InCa Random 0.52 0.44 0.59 0.52 2320 4012 2803 2965 0.45 0.58 0.56 0.41 0.55 0.51
doi:10.1371/journal.pone.0084598.t005
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binding contributors in protein-protein interfaces [53]. Glycine to
valine mutations (Figure S14B) may be deleterious because they
not only increase the volume of the side chain, but also abolish the
conformational flexibility that is unique to glycine, potentially
introducing a more widely felt interface distortion around the
mutated residue. Full listings of microenvironments for each
substitution and area are provided in Dataset S3.
Model for predicting carcinogenicity (drivers) and
comparison with other predictors
Having established which structural parameters may contribute
to a mutation’s carcinogenicity, we created a model, Index of
Carcinogenicity (InCa), using a random forest algorithm [54], to
predict whether a mutation induces a cancer phenotype. The
parameters used and their contributing significance are listed in
Table S4.
We performed a 5 fold cross-validation with 100 iterations,
where 20% of mutations were randomly withheld at each iteration
and used the remainder as a training to train the model. The
model gave an area under the curve (AUC) of 0.88. The optimal
cut-off (which maximizes the distance to the identity (diagonal)
line) was 0.54 and at this threshold, the specificity was 0.83 and
sensitivity 0.77, which is in a similar range to other cancer-specific
methods that train on COSMIC subsets and neutral mutations
such as CHASM [22]. The AUC shows InCa performs better than
Polyphen and SIFT (the receiver operating characteristic (ROC)
curve is shown in Figure 2). The model denoted ‘‘simple structure’’
excludes the microenvironment parameters and a lower AUC in
this model shows that microenvironment parameters confer
predictive contribution. Full prediction metrics for all methods
are given in Table 5.
To ensure that the predictive capacity of our model held despite
possible inherent data bias in driver proteins, we re-ran the same
prediction assessment iterations on the reduced set of 23 proteins.
The InCa AUC dropped to 0.751 and there was a drop in
performance of the other predictors, but because this was greatly
reduced training set, we concluded our predictive parameters were
independent of biases in interface annotations (Figure S15).
We calculated a conservative InCa threshold, based on the
cross-validation InCa scores for mutations in the randomly
withheld sets, below which 99% of the neutral mutations lied, as
0.778. This was used as the cutoff for prediction of a driver.
Application of predictor on COSMIC mutations not
present in the driver list
To compare our method to CHASM, we applied InCa and
CHASM to the mutations in COSMIC that were not in the driver
mutation list. This mutation list consisted of 31471 mutations in
3353 unique proteins. We used the FDR threshold supplied by the
authors, 0.2, to determine which mutations were classed as drivers.
We retained all mutations with a CHASM FDR score below 0.2
and InCa score above 0.778. This resulted in 478 mutations
predicted as drivers by both programs, 458 predicted by InCa only
and 3482 mutations predicted by CHASM only (Figure 3). 193
proteins contained mutations predicted as drivers by both
programs. 239 proteins had mutations predicted as drivers in
InCa only and 690 proteins had some mutations predicted as
drivers by CHASM only. 27052 mutations did not score high
enough to be predicted as drivers by either InCa or CHASM.
We further explored the list of proteins in the InCa only set with
DAVID [55], manual literature mining and inspection. We found
that 216/239 (90%) of proteins had functional associations with
cancer (Table S5). We deduced that a significant amount of
relevant mutations are detected by InCa and CHASM that are not
detected by the other.
To further explore these proteins, we created an induced
protein-protein interaction network (PPIN) using the ROCK web
server [56]. 215 proteins were mapped and we found that by
taking a 1-hop network, 195 of 215 of the proteins (91%) were
connected in a large connected component (Figure 4A). Commu-
Figure 3. Unique mutations and proteins predicted as drivers by InCa and by CHASM from mutations in COSMIC that were not in
the training driver set.
doi:10.1371/journal.pone.0084598.g003
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nities from this network were enriched in GO BP terms that are
characteristic of cancer functions (Table S6). The network
connecting only the list proteins directly contained 217 proteins
and still gave a large connected component containing of 74
proteins. The network excluding orphan nodes is shown in
Figure 4B. Several visually discernible communities were appar-
ent. A few of these were enriched in canonical cancer functions
like signal transduction, cell proliferation and DNA metabolism,
but also in coagulation and RNA processing. Blood coagulation
was recently found to have important contributions to cancer
pathogenesis [57,58]. Similarly, RNA processing also has been
recently shown to be involved in cancer pathogenesis [59,60].
Community membership is listed in Table S7.
Investigation of BARD1 mutation
BARD1 has been previously characterised as an important
contributor to breast and ovarian cancer [61]. We characterised
the BARD1 S660R mutation in more detail (Figure 5). By doing
an energy minimisation on the mutated structure, we found that
the effect is similar to a previously documented C645R mutation
that destabilises the BRCT1 fold [62]. The arginine residue
cannot be accommodated and produces a similar effect to the
C645R and we therefore speculate this could be the mechanism
that contributes to its carcinogenicity.
Domain characterisation of INCA and CHASM driver
mutation predictions
To investigate the distribution of domains in the InCa and
CHASM driver mutation predictions, we plotted these and
compared them (Fig. S16 and Table S8). We found that CHASM
mutations are enriched in kinase domains whereas InCa mutations
are more evenly spread out throughout several Pfam domains.
This might suggest that sequence-based predictors like CHASM
might have a prediction bias for certain genes or domains that is
less pronounced in structure-based predictors.
Application of InCa to a lung adenocarcinoma data set
To further show the applicability if InCa to NGS mutation data
sets, we parsed the mutations from a recent lung adenocarcinoma
study [63] and applied InCa on the missense mutations. The study
contained 7659 missense mutations. We excluded mutations in our
training and testing sets; of the remaining mutations, 622 mapped
to structures and obtained InCa scores. 16 were predicted as
carcinogenic and were all in genes that were associated with
cancer in the literature (Table S9). The top scoring mutation was
in BRAF. Several of these mutations occurred in functional
domains or regions, such as the RNA-recognition motif (RRM1)
domain of SNRPA and the inhibitor TIMP2 binding region of
MMP2. The latter two proteins form a complex highly associated
in other cancers [64,65].
Figure 4. Protein-protein interaction network of genes containing mutations predicted as drivers by InCa only. A) 1-hop network for
the proteins containing mutations predicted as drivers in InCa only. The original proteins are shown as red ellipses. Connecting proteins are shown as
green circles. 29 of 215 proteins are in a giant component. B) Induced network of connections between original proteins only excluding orphans. The
network contains 94 proteins and optimal communities are colour coded. The legend show the top enriched GO BP term in each community.
doi:10.1371/journal.pone.0084598.g004
Figure 5. Energy minimisation of the S660R mutation in BARD1. The top panel shows the mutant Arg residue in the mutant structure
causing a steric clash with the helix opposite. The wild-type (WT) structure is shown in red overlaid with the mutatnt structure in blue. The bottom
panel shows the WT Ser residue.
doi:10.1371/journal.pone.0084598.g005
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Discussion
We have performed an in-depth structural analysis of missense
mutations in both driver mutations from COSMIC and neutral
mutations in 1k. Using these data we have derived parameters for
a new mutation carcinogenicity predictor that is based on
structural and protein interface parameters.
In both datasets it was surface residues that were more often
mutated. This is an expected finding for 1k since surface residue
mutations may play a key role in evolutionary diversification with
low immediate impact on protein structure and function, whereas
protein core mutations tend to have a much more severe effect on
protein structure and stability. Driver mutations found in surface
residues may be detrimental for a number of reasons. Partially
exposed side chains of surface residues were more enriched in
driver mutations, possibly because they have the potential to cause
significant local structural deformation, coupled with the fact that
such substitutions were in principle non-conservative. In addition,
large areas on the protein surface may serve as yet unidentified
interface forming sites for transient or less specific interactions,
particularly considering the very high protein density in the cell,
and hence may be more constrained in tolerating physicochem-
ically dissimilar residues. In agreement with our findings, it was
recently reported that driver mutations are clustered on surface
patches [14].
We observed specific biases in driver for mutated residues and
their resulting amino acid substitutions. Driver mutations were
enriched in mutated glycine and tryptophan residues as well as
buried cysteines. Interestingly, driver mutations occurred less
frequently on a-helices and more often on coils compared to 1k,
implying a more subtle effect than simple secondary structure
perturbation. Talavera et al. also observe that cancer-related
mutations have an overall tendency to occur near specific amino
acids possibly due to a positional bias for proximity to surface
residues and therefore hydrophilic neighbours [14], although it is
difficult to compare the data directly as different distance cut offs
were used. We found that buried cysteines often mutated to
tyrosines and tryptophan and tyrosine residues often mutated to
serine and arginine respectively. Driver mutations are also
commonly found in bond-forming residues in protein binding
interfaces, which may contribute to signaling aberrations and
lesions responsible for the cancer phenotype.
Our findings are generally consistent with the hypothesis that
interface disruptions are a significant factor in generating cancer
phenotypes. The amino acid residues neighbouring mutation sites,
both on the same molecule as well as its binding partner, displayed
significant compositional biases across the driver and 1k datasets
(Figures S12, S13 and Dataset S2, S3). The physicochemical
compatibility of the substitution as well as loss of electrostatic
contacts with the surrounding residues often linked driver
mutations to more adverse interface binding defects.
Using sequence and structural parameters that included residue
neighbourhood, interface electrostatic interactions and the se-
quence conservation as expressed by the FI score [29], we
constructed a predictive additive model that discriminates between
cancer-associated and neutral mutations. While it has been shown
that cancer related mutations occur more often in conserved
residues [14], we showed that using additional structural
information such as neighbouring residues and interface electro-
static bond information yields better prediction performance and
that performance is slightly increased from the inclusion of the FI
score. The performance of the predictor indicates that all these
parameters are important for assessing cancer mutations and in
that respect a simple examination of primary sequence conserva-
tion around the mutated residue may lead to the conclusion that
cancer mutations can occur at any position in the protein [14],
although there are clear mutational hotspots defined by higher
structure orders.
While the caveat of our method is that structural information is
required, we found several instances where FI scores are unavailable,
presumably due to insufficient sequence information or size of protein
families required for the computation. For these cases, our structural
method can still be used to predict cancerous character.
A comprehensive analysis of neighbouring residues of candidate
mutations would give value for discerning future potential cancer
mutations. With the advent of structural genomics initiatives, it
will be increasingly practical to investigate structures of unchar-
acterized proteins if they are relevant and more data will be
available. While structural predictors have been used extensively
in previous studies [23,25], we show that added value can be
obtained from structural information from comprehensive analy-
ses such as those in PISA and information of neighbouring
residues of the mutation.
In this work we focused on the classification of missense
mutations as their effect on protein function is more difficult to
interpret. While the 1000 Genomes project derives data from non-
diseased individuals it may contain a number of mutations that can
drive or predispose to cancer later in life. While in its current form
InCa may be subject to these issues, it may be possible to fine tune
its resolving power with interaction network perturbation analysis
features particularly as the cancer phenotype often is the result of
multiple signaling lesions [66].
The observation that CHASM predictions were enriched in
kinase domains suggests there could be a degree of gene-centricity
that is created by the datasets used for training and the method.
We also observed instance where FI scores gave false positives,
such as the BRAF D594V mutation, which decreases ERK
stimulation [67] but has a high FI score (4.46). The mutation also
occurred in our training data set and therefore highlighted that all
predictors trained on non-experimentally validated and charac-
terised drivers may potentially suffer from a few false positives in
the training set. Our results that InCa and CHASM detect
different mutations, albeit with large overlap, suggest that several
different methods should be used when determining mutation
carcinogenicity and that shortcomings of each individual methods
in isolation should be considered. While all current methods for
predicting the effects of single mutations are powerful, the effect of
mutations is often combinatorial and so the context of each
mutation should be taken into account for better biological
interpretation.
Supporting Information
Dataset S1 Data fame of mutations with all parameters.
(ZIP)
Dataset S2 Neighbouring residue profiles for mutations
classed by WT residue.
(ZIP)
Dataset S3 Neighbouring residue profiles for mutations
classed by substitution.
(ZIP)
Figure S1 Unique mutations and proteins in the cancer
driver and neutral datasets.
(TIF)
Figure S2 Distributions of amount of mutations per
protein.
(TIF)
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Figure S3 Background distribution of amino acid
frequencies in 1000 Genomes and COSMIC. A) Normal-
ised frequencies (denoted P(x) for density) of amino acids in each
set. The frequencies are ordered according to average value. B)
Normalised frequencies for each sample divided by area. C)
Pearson correlation coefficients of each set pair. Smooth trendlines
are overlaid in red on plots in the bottom left part of the panel. D)
as C) for each sample divided by area. The dataset each series
denotes is described below. PDB, NR, Hsa: All non-redundant
human crystallised sequences 1k: 1000 Genomes set of non-
redundant human crystallised sequences COSMIC: Cosmic set of
non-redundant human crystallised sequences Uniprot: Entire
Uniprot sequences Uniprot PDB: Entire Uniprot sequences which
have PDB entries Uniprot 1k: Entire Uniprot sequences in the
1000 Genomes set Uniprot COSMIC: Entire Uniprot sequences
in Cosmic Uniprot 1k and COSMIC: Entire Uniprot sequences in
Cosmic and 1000 Genomes.
(TIF)
Figure S4 Mutation severity in neutral and driver
mutations by physicochemical change of substitution,
mutational permissiveness according to BLOSUM 62,
Dayhoff, FI and distance to interface. The first row shows
plots of change in amino acid physiochemical character incurred
by the substitution. The driver mutations show a greater change in
physiochemical character, thus presumably incurring a greater
disruption to protein stability/function. The second row shows
boxplots of mutation substitution severity according to the amino
acid substitution values in BLOSUM 62 (EBI). The 1k mutations
hover around 0, whereas the driver mutations have less permitted
mutability. Rows 3 and 4 show that same using Dayhoff (EBI) (see
text) and FI scores. Rows 5 and 6 show minimum and mean
distances to interfaces. Because unique residues can have multiple
PDB files and each PDB file can have many interfaces, there are
several distances from each residue to each interface. The
proximity of driver mutations to the interface suggests that cancer
mutations tend to disrupt interfaces.
(TIF)
Figure S5 Mutation severity in neutral and driver
mutations by physicochemical change of substitution,
mutational permissiveness according to BLOSUM 62,
Dayhoff, FI and distance to interface, using the reduced
set of 23 proteins with both neutral and driver
mutations.
(TIF)
Figure S6 Propensities in mutations split by area and
2ry structure separately. A) Normalised frequency of
occurrences of mutations in each area. Cancer mutations occur
more frequently in buried and interface areas than neutral
mutations. B) Normalised frequency of occurrences of mutations
in secondary structures. Most carcinogenic mutations occur in
coils and beta sheets and less in helices. There is a small but
significant difference (Fisher’s test with a two-sided alternative
hypothesis) between the driver and 1k samples in both cases. C)
Fractions of observed normalised frequency to expected normal-
ised frequency (all residues in proteins) for each area. D) Fractions
of observed normalised frequency to expected normalised
frequency for each secondary structure.
(TIF)
Figure S7 Propensities in mutations split by area and
2ry structure separately, using the reduced set of 23
proteins with both neutral and driver mutations.
(TIF)
Figure S8 Enriched mutations in area, secondary
structure and WT residue comparing neutral and driver
mutations. Red denotes enriched classes in drivers and blue
denotes enriched classes in neutral mutations. A) Enrichment in
driver mutations divided by area and WT residue (so). B)
Enrichment in driver mutations divided by area, secondary
structure and WT residue (so).
(TIF)
Figure S9 Heatmaps of normalised substitution frequen-
cies and enrichment comparing neutral and driver
mutations. Red denotes enriched classes in drivers and blue
denotes enriched classes in neutral mutations. A) Driver/neutral
fraction of normalised frequencies for mutations by area and
substitution. B) Statistically overrepresented substitution frequen-
cies by area (so).
(TIF)
Figure S10 Heatmaps of normalised substitution fre-
quencies and enrichment comparing neutral and driver
mutations for mutation classes separated by area and
secondary structure. Red denotes enriched classes in drivers
and blue denotes enriched classes in neutral mutations. A) driver/
neutral fraction of normalised frequencies for mutations by area
and substitution. B) Statistically overrepresented substitution
frequencies by area (so).
(TIF)
Figure S11 Neighbouring residue profile of targeted
wild-type buried Cys mutations in the 5 A˚ vicinity.
(TIF)
Figure S12 Salt bridge enrichment in interface residues
for charged residues targeted by COSMIC mutations.
Densities (denoted P(x)) are shown for mutations of each amino
acid in both sets with their associated p-values comparing 1k and
COSMIC with a two-sample Wilcoxon test using a one-sided
alternative hypothesis.
(TIF)
Figure S13 Neighbouring residue profiles of mutated
interface residues in the 5 A˚ vicinity. The 5 A˚ neighbour-
hood profiles are shown grouped by mutated wild-type residue and
by area. Shown are signed p-values using a two-sample Wilcoxon
test. Red denotes enrichment in drivers and blue denotes enriched
classes in neutral mutations.
(TIF)
Figure S14 Neighbouring residue profiles for FRS muta-
tions and GRV mutations in the 5 A˚ vicinity of the
muatations. Profiles of neighbouring amino acid residues on
the mutated side of the interface are denoted by their codes and
those on the opposite side of the interface are denoted with
‘‘Opp’’. Neighbouring residues of interface phenylalanine muta-
tions in neutral mutations and drivers. Normalised (relative)
frequencies (P(x)) are shown for each amino acid for 0–5 A˚. The
‘‘Opp’’ suffix denotes the molecule on the opposite side of the
interface to the mutated molecule.
(TIF)
Figure S15 ROC curve for Inca and other mutation
predictors using the reduced set of 23 proteins with both
neutral and driver mutations.
(TIF)
Figure S16 Pfamdomaindistribution in InCaandCHASM
predicted driver mutations. A) InCa only. B) CHASM only.
(TIF)
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Table S1 Definitions of topological areas.
(XLS)
Table S2 Physicochemical properties of amino acids.
(XLS)
Table S3 Top mutated proteins for neutral mutations
and driver muations.
(XLS)
Table S4 Model parameters and importance in InCa.
The %incMSE is the increasing in mean of the error of a tree
(mean square error (MSE)) for regression and misclassification in
the forest when the observed values of this variable are randomly
permuted in the ‘‘out of bag’’ samples. The IncNodePurity is the
total decrease in node impurities from splitting on the variable,
averaged over all trees.
(XLS)
Table S5 Cancer functions for proteins containing
mutations that were predicted as drivers by InCa only.
(XLS)
Table S6 Enriched GO BP terms in communities of the
protein-protein interaction network of proteins contain-
ing mutations that were predicted as drivers by InCa
only.
(XLS)
Table S7 Community membership of proteins in the
protein-protein interaction network of proteins contain-
ing mutations that were predicted as drivers by InCa
only.
(XLS)
Table S8 Pfam domain counts for genes from COSMIC
mutations not in drivers that were predicted as drivers
by InCa only and CHASM only.
(XLS)
Table S9 InCa scores and predictions for the lung
adenocarcinoma data set.
(XLS)
Text S1 Supporting methods.
(DOC)
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